Skip to content
sellModerate cluster of 5

Lawrence Otto Klein sold $235k of ORKA

Chief Executive Officer at Oruka Therapeutics, Inc.. 2,452 shares at an average of $95.71, traded Sep 15, 2026, filed Sep 15, 2026.

Warning score
53
Value
$235k
2,452 shares
Holdings after
923,128
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $235k at market
    +13
  • Share of holdings sold
    Sold 0.3% of holdings
    0
  • Cluster
    5 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ORKAOct 12, 2026 · close 80.35
Since filing Sep 15, 2026: -12.9%SPY +3.0% · excess -15.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000907654-26-000096, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 15, 2026SOpen-market sale
Common Stock
-2,452$95.71$235k923,12829 d ago

Related signals

Other insiders at Oruka Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
Pro nowfree Oct 20, 2026
ORKAsell 210b5-1
Oruka Therapeutics, Inc.
Arjun Agarwal
Senior Vice President, Finance
$806k
9,999 shares
-41%
30Weak
ORKAsell 310b5-1
Oruka Therapeutics, Inc.
Lawrence Otto Klein
Chief Executive Officer
$2.1M
25,000 shares
-3%
17Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Arjun Agarwal
Senior Vice President, Finance
$51k
533 shares
-4%
29Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Paul T Quinlan
General Counsel
$936k
10,000 shares
-25%
29Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Arjun Agarwal
Senior Vice President, Finance
$926k
10,019 shares
-40%
21Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Joana Goncalves
Chief Medical Officer
$734k
7,947 shares
-20%
44Moderate
ORKAsell 5
Oruka Therapeutics, Inc.
Laura Lee Sandler
Chief Operating Officer
$87k
906 shares
-0%
40Moderate
ORKAsell 5
Oruka Therapeutics, Inc.
Paul T Quinlan
General Counsel
$99k
1,039 shares
-3%
30Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Lawrence Otto Klein
Chief Executive Officer
$6.9M
75,000 shares
-7%
17Weak
ORKAsell 510b5-1
Oruka Therapeutics, Inc.
Laura Lee Sandler
Chief Operating Officer
$459k
5,000 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.